Novel Applications of JAK Inhibitors in Water Quality, Pipeline Corrosion, Plant Health, Medical Implants, and Agriculture

Publication ID: 24-11857669_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Novel Applications of JAK Inhibitors in Water Quality, Pipeline Corrosion, Plant Health, Medical Implants, and Agriculture,” Published Technical Disclosure No. 24-11857669_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857669_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,669.

Summary of the Inventive Concept

This inventive concept leverages the core technology of JAK inhibitors to address unmet needs in various industries, including water quality monitoring, pipeline corrosion prevention, plant health management, medical implant biofilm detection, and agricultural crop yield improvement.

Background and Problem Solved

The original patent disclosed methods and compositions for treating diseases of the gastrointestinal tract with JAK inhibitors. However, the limitations of this technology lie in its narrow application scope. The new inventive concept addresses this limitation by exploring novel applications of JAK inhibitors in unrelated fields, thereby expanding the technology's potential impact and value.

Detailed Description of the Inventive Concept

The inventive concept encompasses five distinct applications of JAK inhibitors: 1) a system for monitoring water quality, where an ingestible device releases a JAK inhibitor to treat aquatic life affected by pollutants; 2) a method for preventing corrosion in pipelines by administering a JAK inhibitor via an ingestible device; 3) a composition for treating fungal infections in plants, combining a JAK inhibitor with a plant growth promoter; 4) a device for detecting and treating biofilm formation on medical implants, using an ingestible device that releases a JAK inhibitor and a sensor that detects biofilm formation; and 5) a system for improving crop yields, comprising a network of soil sensors and an ingestible device that releases a JAK inhibitor to treat soil microorganisms.

Novelty and Inventive Step

The new inventive concept introduces novel and non-obvious applications of JAK inhibitors, departing from the original patent's gastrointestinal tract focus. The inventive step lies in recognizing the potential of JAK inhibitors to address diverse problems across various industries, thereby expanding the technology's scope and value.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include different types of sensors, ingestible devices, or JAK inhibitors. Variations could involve adapting the technology for use in other industries, such as environmental remediation or cosmetics.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various markets, including water quality monitoring, pipeline maintenance, agricultural technology, medical devices, and plant health management. The market size for these applications is substantial, with opportunities for partnerships, licensing, and new product development.

CPC Classifications

SectionClassGroup
A A61 A61K9/0009
A A61 A61K9/0004
A A61 A61K9/0053
A A61 A61K31/519

Field of Art

Pharmaceutical drug delivery systems, biotechnology, and medical device technologies with a focus on targeted drug administration and biological inhibition mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in pharmaceutical sciences, bioengineering, or chemical engineering, possessing expertise in drug delivery mechanisms, biological inhibition techniques, and interdisciplinary technology applications

Obviousness Rationale

A PHOSITA would recognize that JAK inhibitors represent a versatile molecular mechanism with broad potential applications beyond gastrointestinal treatments. The source patent's fundamental disclosure of targeted JAK inhibitor delivery provides a clear technological foundation for exploring alternative industrial and environmental applications. The PTD's variations represent predictable extensions of known JAK inhibition principles, applying established drug delivery and sensor technologies to novel problem domains.

Obvious Combinations & Variations

Source Patent Element
Orally administered JAK inhibitor with controlled plasma concentration
PTD Variation
Ingestible devices releasing JAK inhibitors in water quality, pipeline, and agricultural monitoring systems
Obviousness Reasoning
Known drug delivery technologies enable precise controlled release, and sensor integration represents a standard engineering approach to monitoring biological systems
Source Patent Element
Targeted delivery of JAK inhibitor to specific gastrointestinal locations
PTD Variation
Localized release of JAK inhibitors in pipeline corrosion prevention and medical implant biofilm treatment
Obviousness Reasoning
Predictable application of site-specific drug delivery principles to alternative technological domains with known microbial interaction challenges
Source Patent Element
Method of treating biological systems using JAK inhibition
PTD Variation
Expanding JAK inhibitor applications to plant health, soil microorganism management, and aquatic ecosystem treatment
Obviousness Reasoning
Established scientific understanding of JAK pathway's broad biological regulatory mechanisms suggests transferable intervention strategies across different biological systems
Source Patent Element
Pharmaceutical composition focusing on minimal systemic absorption
PTD Variation
Sensor-triggered, targeted release systems minimizing unintended biological interactions
Obviousness Reasoning
Precise dosage control and targeted delivery represent known pharmaceutical engineering techniques for managing biological interventions
Source Patent Element
Therapeutic agent targeting specific biological pathways
PTD Variation
Multifunctional compositions combining JAK inhibitors with growth promoters or environmental sensors
Obviousness Reasoning
Combination of complementary biological agents represents a standard approach in biotechnological innovation, following predictable design principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857669 and the comprehensive disclosure demonstrating JAK inhibitor adaptability, a person of ordinary skill in the art would find the proposed technological variations obvious and lacking inventive step. The published technical disclosure provides sufficient prior art evidence that the claimed innovations represent predictable extensions of existing pharmaceutical and biological intervention technologies, thereby rendering subsequent similar claims obvious under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,669
TitleTreatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
Assignee(s)Biora Therapeutics, Inc.